Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
复制标题
DOI：
10.1056/nejmoa1307684
复制
发表时间：
2013-10-03
影响因子：
158.5
通讯作者：
Simmons, D.
中科院分区：
文献类型：
--
作者：
Scirica, Benjamin M.;Bhatt, Deepak L.;Simmons, D.
BackgroundThe心血管的安全性和有效性，目前许多抗高血糖药物，包括沙格列汀，二肽基肽酶4（DPP-4）抑制剂，是unclear.MethodsWe随机分配16,492例2型糖尿病患者的历史，或有风险，心血管事件接受沙格列汀或安慰剂，并遵循他们的中位数为2.1年。允许医生调整其他药物，包括降糖药。主要终点是心血管死亡、心肌梗死或缺血性strok.ResultsA主要终点事件发生在613例沙格列汀组和609例安慰剂组患者中（根据2年Kaplan-Meier估计，分别为7.3%和7.2%;沙格列汀的风险比为1.00; 95%置信区间[CI]，0.89至1.12;优效性P=0.99; P
BackgroundThe cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.MethodsWe randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke.ResultsA primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P